

Oregon Health & Science University Hospital and Clinics Provider's Orders



ADULT AMBULATORY INFUSION ORDER
Agalsidase Beta (FABRAZYME)
Infusion

Page 1 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK	\checkmark	TO BE ACTIVE.

weign	t:kg
Allergi	es:
Diagno	osis Code:
Treatm	nent Start Date: Patient to follow up with provider on date:
This	plan will expire after 365 days at which time a new order will need to be placed
GUIDE	ELINES FOR ORDERING
	Send FACE SHEET and H&P or most recent chart note.
	Indicated for use in patients with Fabry disease. Reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types
3.	Please encourage patients to enroll in the Fabry registry by visiting <u>www.fabryregistry.com</u> or calling 1-800-745-4447.
4.	Patients with advanced Fabry disease may have compromised cardiac function which may predispose them to a higher risk of severe complications from infusion reactions.
Note t	MEDICATIONS: (Administer 30 minutes prior to infusion) to provider: Please select which medications below, if any, you would like the patient to receive to treatment by checking the appropriate box(s)
	acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit
	diphenhydrAMINE (BENADRYL) capsule, 50 mg, oral, ONCE, every visit
	loratadine (CLARITIN) tablet, 10 mg, oral, ONCE, every visit
	(Choose as alternative to diphenhydrAMINE if needed)
MEDIO	CATIONS:
Ag we	alsidase beta (FABRAZYME) 1 mg/kg = mg in sodium chloride 0.9% IV infusion, ONCE, every 2 eks x doses (Pharmacist will round dose to nearest 5 mg vial and modify during order rification)
mg	minister using an in-line low protein binding 0.2 micron filter. Initial infusion: Rate should not exceed 15 J/hr. Subsequent infusions if no infusion reactions: rate may be increased in increments of 3 to 5 mg/hr to by a total infusion time of no less than 1.5 hours. Total volume will be between 50-500 mL based on

≤ 35 mg	50 mL minimum total volume
35.1 – 70 mg	100 mL minimum total volume
70.1 – 100 mg	250 mL minimum total volume
> 100 mg	500 mL minimum total volume

calculated dose:



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER

Agalsidase Beta (FABRAZYME) Infusion

Page 2 of 3

ACCOUNT	NO.
MED. REC.	NO.
NAME	

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

BIRTHDATE

NURSING ORDERS:

- 1. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.
- 2. VITAL SIGNS Monitor and record vital signs, tolerance, and presence of infusion-related reactions prior to infusion, with every rate increase, then hourly until infusion is complete.
- 3. Observe patient for 60 minutes following infusion (unless prescriber indicates this is not necessary).
- 4. Reschedule patient for next weekly infusion.

HYPERSENSITIVITY MEDICATIONS:

- 1. NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
- 2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

	patient (who is identified at the top of this form);	
I hold an active, unrestricted license that corresponds with state where y state if not Oregon);	e to practice medicine in: Oregon ou provide care to patient and where you are curre	(check box antly licensed. Specify
	#(MUST BE COMPLETED within my scope of practice and authorized by law to patient identified on this form.	
Provider signature:	Date/Time:	
Printed Name:	Phone: Fa	ax:



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
Agalsidase Beta (FABRAZYME)
Infusion

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Page 3 of 3

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Central Intake:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

□ Beaverton

OHSU Knight Cancer Institute 15700 SW Greystone Court Beaverton, OR 97006

Phone number: 971-262-9000 Fax number: 503-346-8058

☐ Gresham

Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030

Phone number: 971-262-9500 Fax number: 503-346-8058

□ NW Portland

Legacy Good Samaritan campus Medical Office Building 3, Suite 150 1130 NW 22nd Ave Portland, OR 97210

Phone number: 971-262-9600 Fax number: 503-346-8058

□ Tualatin

Legacy Meridian Park campus Medical Office Building 2, Suite 140 19260 SW 65th Ave Tualatin, OR 97062

Phone number: 971-262-9700 Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders